




The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 142% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 356%, being 100% points above the market average of 256%.

| Input Variable                              | Value in<br>1000 USD | Output Variable             | Value in<br>1000 USD |
|---------------------------------------------|----------------------|-----------------------------|----------------------|
| Assets, Current                             | 5,228                | Assets                      | 5,228                |
| Cost of Goods Sold                          | 0                    | Liabilities                 | 217                  |
| Intangible Assets                           | 0                    | Expenses                    | 3,270                |
| Liabilities, Current                        | 217                  | Revenues                    | 0                    |
| Liabilities, Non-Current                    | 0                    | Stockholders Equity         | 5,012                |
| Other Assets                                | 0                    | Net Income                  | -3,265               |
| Other Compr. Net Income                     | 0                    | Comprehensive Net Income    | -3,265               |
| Other Expenses                              | 3.7                  | BaseVar                     | 4,360                |
| Other Liabilities                           | 0                    | ECR before LimitedLiability | 281%                 |
| Other Net Income                            | 5.2                  | Economic Capital Ratio      | 356%                 |
| Other Revenues                              | 0                    |                             |                      |
| Property and Equipment                      | 0                    |                             |                      |
| Research and Development                    | 1,224                |                             |                      |
| Selling, General and Administrative Expense | 2,043                |                             |                      |